Tilidon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tilidon

Property Description
Active ingredient Domperidone
Form Oral forms (Tablet, Suspension/Syrup)
Pharmacological class Dopamine Antagonist and Prokinetic Drug
General purpose Relieves nausea and prevents vomiting
Origin Synthetic organic compound

Identity, Classification, and Composition: The Nature of Domperidone

Tilidon is a medication whose identity is centered on the active ingredient, Domperidone. Domperidone is the International Nonproprietary Name (INN) for the compound. This medicine is formally categorized as a dopamine antagonist and is specifically classified as a prokinetic drug. Domperidone is a synthetic organic compound derived from the benzimidazole chemical class, and it is supplied as a single-ingredient product designed exclusively for oral administration. The medication is available in various oral forms, most commonly as a solid tablet and as a liquid oral suspension or syrup, a versatility in presentation that accommodates different patient groups.


Mechanism Concept and General Purpose

Domperidone is clinically recognized for stimulating motility of the upper gastrointestinal tract by blocking dopamine receptors in the gut wall, leading to faster movement. This action establishes the general therapeutic purpose of Tilidon as a specialized antiemetic, generally aiming to help relieve the distressing sensation of nausea and prevent episodes of vomiting. Its capability stems from Domperidone being a peripherally acting agent, concentrating its effect on the digestive organs and the specific area in the brainstem responsible for controlling the vomiting reflex (the chemoreceptor trigger zone).

Regulatory References

  1. Domperidone - NCBI LactMed Monograph

What side effects are possible with Tilidon?

Possible side effects and safety information

The officially documented safety profile for Tilidon (Domperidone) is structured around potential cardiac risks, hormonal effects, and specific population constraints, as defined by regulatory bodies. Adverse reactions are classified by frequency, helping to distinguish between common and rare occurrences.

Frequency-Classified Adverse Reactions

The most frequently reported effect listed as Common in regulatory documents is dry mouth. Effects categorized as Uncommon typically involve the gastrointestinal system (e.g., diarrhoea), nervous system (e.g., headache, somnolence), and psychiatric disorders (e.g., anxiety). Reactions with a frequency of Not Known include serious cardiac events.

Serious Safety Considerations

The most clinically significant safety element is the risk of serious ventricular arrhythmias, including QTc prolongation and Torsade de Pointes, which can lead to sudden cardiac death. Other serious reactions officially documented are severe anaphylactic reactions.

Safety Restrictions and Special Populations

The regulatory label imposes explicit restrictions. Tilidon is contraindicated in patients with pre-existing cardiac conditions (such as congestive heart failure) or moderate or severe hepatic impairment. The risk of serious cardiac events is noted to be higher in older patients (over 60 years) and is associated with higher daily doses. Furthermore, the medication should not be used concurrently with QT-prolonging drugs or potent CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose with Tilidon (Domperidone) has been officially documented, with reports primarily noting cases in infants and children. The clinical manifestations of overdosage involve two primary physiological systems: the Central Nervous System (CNS) and the cardiovascular system.

Documented CNS effects include signs of altered consciousness such as somnolence, confusion, disorientation, and agitation. Overdosage may also present with serious neurological events, including convulsion (fit) and extrapyramidal reactions, which are recognized as uncontrolled movements, irregular eye movements, and abnormal posture like a twisted neck.

Crucially, the overdose profile highlights the potential for severe cardiovascular complications. The official labeling mandates that Electrocardiogram (ECG) monitoring be undertaken due to the risk of QT interval prolongation, which can lead to life-threatening ventricular arrhythmias and, potentially, sudden cardiac death.

When overdose is suspected, official guidance states that immediate medical attention must be sought straight away, particularly if the patient experiences a seizure or a very fast or irregular heartbeat. Since no specific antidote is known, supportive measures are required, with standard symptomatic treatment being the mandated immediate action. Officially described procedural steps include gastric lavage and activated charcoal, and anti-Parkinsonian agents may be utilized for managing extrapyramidal reactions.

Therapeutic Uses of Tilidon

What Tilidon treats: main uses and benefits

Tilidon is a medication primarily used for the management of severe pain. It belongs to a class of drugs known as analgesics, specifically combining an opioid component with an opioid antagonist to help manage pain while modulating certain side effects.

Primary Indications

The main application of Tilidon is the treatment of intense, chronic, or persistent pain that has not responded sufficiently to non-opioid pain relievers. It is typically reserved for conditions where continuous, around-the-clock pain management is required. Common areas of use include:

  • Severe Chronic Pain: Management of long-term pain associated with degenerative conditions or neurological issues.
  • Post-Surgical Recovery: Use in clinical settings for acute, high-intensity pain following major surgical procedures.
  • Cancer-Related Pain: Treatment of pain resulting from malignant diseases or intensive oncological therapies.

Therapeutic Benefits

The formulation of Tilidon is designed to provide several therapeutic advantages for patients dealing with significant pain levels:

  • Potent Pain Relief: The active components work on the central nervous system to alter the perception of pain, providing relief when standard analgesics are ineffective.
  • Consistent Efficacy: In its prolonged-release forms, the medication provides a steady delivery of the active substance, helping to maintain stable pain control throughout the day and night.
  • Improved Quality of Life: By reducing high-intensity pain, the medication can help patients maintain better mobility and rest, which are often disrupted by chronic pain conditions.
  • Balanced Action: The inclusion of an antagonist component is intended to support the primary analgesic effect while addressing specific physiological responses to the medication.

Eligibility and Restrictions for Use

Eligibility Profile: Official Restrictions

Tilidon (Domperidone) use is strictly regulated by international health authorities, defining precise eligibility rules for patients. The medicine is primarily authorized for Adults and Adolescents aged 12 years or older who weigh 35 kg or more.

Contraindicated Populations (Must Not Use)

Tilidon is contraindicated and must not be used by individuals with the following official exclusions:

  • Cardiac Conditions: Patients with known existing QTc prolongation, significant electrolyte disturbances (such as hypokalaemia), or underlying cardiac diseases, including congestive heart failure.
  • Organ/Physiological Impairment: Patients with moderate or severe hepatic impairment (liver failure).
  • Gastrointestinal Risk: When stimulating gastric motility could be harmful, such as in cases of gastrointestinal hemorrhage, obstruction, or perforation.
  • Other: Patients with a known prolactin-releasing pituitary tumor.

Use Limitations and Restrictions

  • Pediatrics: The medicine is no longer authorized for children younger than 12 years of age or those weighing less than 35 kg, primarily due to a lack of established efficacy in this group.
  • Geriatrics: Patients older than 60 years are recognized as having a higher risk of serious cardiac adverse events.
  • Kidney Impairment: Patients with severe renal impairment require a mandated reduction in dosing frequency.
  • Pregnancy and Lactation: Use during pregnancy is generally limited to when the therapeutic benefit is fully justified. Use is not recommended in breastfeeding individuals, as the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Tilidon (Domperidone) is governed by specific regulatory constraints targeting systemic drug exposure and cardiac risk.

Contraindicated Combinations and Exposure Risk

Co-administration is formally contraindicated with two major drug categories. The first category involves potent CYP3A4 inhibitors (such as certain azole antifungals and macrolide antibiotics). Inhibition of this key metabolic pathway, along with effects on the P-glycoprotein (P-gp) transporter, causes a significant, multi-fold increase in Domperidone plasma concentration and reduced clearance. The second contraindicated category involves QTc-prolonging medicinal products (including specific antiarrhythmics), due to a documented additive pharmacodynamic effect that increases the risk of serious ventricular arrhythmias. This elevated interaction risk is noted in official documents as being of higher relevance in patients older than 60 years and those with moderate to severe hepatic impairment.

Timing and Absorption

Regarding co-administration, substances that reduce gastric acidity (e.g., antacids or antisecretory agents) should not be taken simultaneously with Tilidon, as they impair oral absorption and bioavailability. Furthermore, the absorption of oral Domperidone is officially documented as delayed if the medicine is taken after food.

Mechanism of Action

The mechanism of Tilidon (Domperidone) is centered on the selective antagonism of dopamine D2 and D3 receptors, resulting in a dual physiological consequence: modulation of upper GI smooth muscle tone and inhibition of signal transduction at the Chemoreceptor Trigger Zone (CTZ).

Selective Blockade of Peripheral Dopamine Receptors

Tilidon acts as a selective antagonist, primarily binding to receptors located outside the brain in the walls of the gastrointestinal (GI) tract and the CTZ. This mechanism is notable due to its low penetration across the blood-brain barrier, which confines its primary action to peripheral receptor populations.

Modulation of Upper GI Motility

By blocking D2 receptors in the stomach wall, Domperidone removes dopamine’s natural inhibitory brake on smooth muscle contraction. This action enhances the signaling of acetylcholine, the neurotransmitter responsible for stimulating GI muscle movement. The resulting physiological consequence is enhanced antro-duodenal peristalsis (coordinated forward movement) and increased pressure in the Lower Esophageal Sphincter (LES), representing a shift in smooth muscle activity in the upper digestive tract.

Interruption of the Emesis Signaling Cascade

The drug directly engages the Vomiting Reflex Pathway by blocking D2 receptors located in the CTZ. This blockade disrupts the pathway through which blood-borne substances trigger the physical expulsion reflex. This action suppresses the primary signal that initiates the emesis cascade, resulting in the interruption of signal transmission to the central Vomiting Center.

Dosage and Administration Information

How to Use Tilidon: Administration Principles

Tilidon, which contains domperidone, is used according to specific administration principles. The approach focuses on administering the lowest effective dose for the shortest possible duration necessary to manage symptoms, with treatment for acute episodes generally limited to a maximum of seven days.

Administration and Dosage Schedules

Tilidon is administered via the oral route (tablets, suspension, and orodispersible tablets) and the rectal route (suppositories). For oral use, the medication is limited to a maximum daily dose of 30 mg in adults and adolescents weighing ge 35 kg. The standard dose for this group is 10 mg up to three times per day.

Administration Parameter Administration Guidance
Dosing Frequency Up to three times per day (oral) or twice daily (rectal)
Dose Interval A minimum of 8 hours is required between oral doses
Timing with Food Must be taken before meals (fasted state) to optimize absorption
Missed Dose Rule If a dose is missed, it must be omitted; a double dose is not permitted

Population-Specific Use

For children weighing less than 35 kg, the dose is calculated based on body weight at 0.25 mg/kg up to three times daily; standard tablets are not suitable for this population. In cases of severe renal impairment, the dosing frequency must be reduced to once or twice daily due to the body's prolonged elimination time for the medication. These measures ensure standardized administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tilidon (Domperidone)

This overview details the type of formal research that has been conducted on Domperidone, the active ingredient in Tilidon. It focuses on how studies were designed, what they measured, and what remains uncertain in the research landscape, drawing on research from authoritative governmental and peer-reviewed scientific sources.


Evidence for Acute and Chronic Nausea and Vomiting

Research examining nausea and vomiting has primarily involved short-term Randomized Controlled Trials (RCTs). These studies examined outcomes related to physical discomfort, monitoring changes in nausea scores and the frequency of vomiting episodes. Studies monitored symptom patterns over defined time intervals. However, some of the evidence in this area is derived from older trials, and the follow-up durations were limited, generally focusing on immediate symptom patterns.


Evidence for Gastroparesis (Delayed Gastric Emptying)

The research for gastroparesis, a condition marked by functional limitations related to delayed stomach emptying, was evaluated in observational settings and in studies exploring short-term symptom changes. Studies were evaluated in adults with diabetic, idiopathic, or post-surgical forms of the condition. Research examined outcomes reflecting daily functioning or activity level and patient-reported outcomes describing perceived discomfort, using measures like the Gastroparesis Cardinal Symptom Index (GCSI).

However, the certainty remains low because the evidence quality varies across studies, with a significant reliance on non-randomized data. The findings were mixed, and there is limited information for long-term outcomes for this use.


The Overall Research Landscape and Uncertainties

The overall evidence landscape for Tilidon data show patterns related to a research base where evidence quality varies across studies and time periods. Key limitations include that the majority of the highest-quality RCTs focused only on short-term symptom changes. As a result, long-term effects are not fully established for any chronic condition. Comparative evidence is lacking for some of the chronic conditions, and data for certain groups remain insufficient, particularly children and those with multiple comorbidities. Research does not determine whether an individual will respond similarly.

Key Studies & References

  1. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis
  2. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia

Frequently Asked Questions (FAQ)

Common questions about Tilidon (FAQ)


Q: Can Tilidon be taken with common pain relievers like ibuprofen?

Official product information on potential drug interactions primarily focuses on specific combinations that are formally contraindicated. These high-risk categories involve medicines that are potent CYP3A4 inhibitors or those that prolong the QTc interval. Common pain relievers, such as ibuprofen, are generally not specified in these high-risk contraindication categories in official documents.


Q: Does Tilidon interact with birth control pills?

According to official product information, this drug generally is not expected to affect the function of most hormonal contraceptive methods. This description of a lack of interaction applies to both the combined pill and the progestogen-only pill.


Q: Is it true that Tilidon can affect sleep?

The official safety profile for the medication includes somnolence, which means drowsiness or feeling sleepy. Somnolence is listed as an Uncommon adverse reaction in official documents, indicating it is a known possibility reported in studies.


Q: Is it normal to have mild headaches when starting Tilidon?

Headache is listed in the official safety information as an Uncommon adverse reaction, meaning it is a known possibility reported during trials. However, regulatory documents do not specify whether a headache is typically mild or occurs only when first starting the medication.


Q: Can Tilidon make you feel tired or dizzy?

Official safety information reports both somnolence (drowsiness or feeling tired) and dizziness as known adverse reactions. Official warnings relate caution when driving or operating machinery to the presence of these potential effects.


Q: Is Tilidon known to cause skin rashes?

While less common, the official safety profile notes that severe anaphylactic reactions are possible, which are serious allergic responses. Allergic reactions to medications may manifest as less severe effects, such as skin rashes or hives.


Q: Is Tilidon a type of antibiotic?

Official classification indicates the drug is not an antibiotic. The drug is officially classified as a Dopamine Antagonist and a Prokinetic Drug, a functional classification that works on the digestive system.


Q: How long does it typically take for Tilidon to start working?

Regulatory-based consumer information indicates that the drug usually begins to work relatively quickly to relieve symptoms. The medication is often described as starting to act within approximately 30 to 60 minutes after taking a dose.


Q: Are there any long-term effects of taking Tilidon?

Official research overviews indicate that the majority of studies have focused on short-term symptom changes over limited durations. Consequently, regulatory documents state that the long-term effects are not fully established for chronic use of the drug.


Q: Can Tilidon affect my ability to drive or operate machinery?

Due to the possibility of effects like dizziness or drowsiness (somnolence), official warnings relate caution when driving or operating machinery to the presence of these potential effects. This advice is provided until the individual knows how the medicine affects them.


Q: Does Tilidon need to be stored in the refrigerator?

Official storage instructions specify that the medicine should be kept at controlled room temperature, typically below 30 C (86 F). It must be protected from freezing, light, and moisture, and refrigeration is not required as a standard measure.


Q: What happens if I miss a dose of Tilidon?

Official guidance provides specific rules for managing a missed dose. These rules emphasize the importance of omitting the missed dose and not doubling up, which helps ensure the required time interval between doses is maintained.


Q: Is Tilidon used to treat anxiety?

Official indications show the medication is authorized only for the relief of nausea and the prevention of vomiting. It is not approved by regulatory authorities for the treatment of anxiety or other psychiatric conditions.


Q: Can I drink alcohol while taking Tilidon?

Official warnings relate to the consumption of alcohol, as alcohol may increase the risk of side effects such as tiredness or dizziness (somnolence). Due to this possibility, a limitation or avoidance of alcohol is noted in the drug information.


Q: How is Tilidon different from a vitamin supplement?

This is a prescription medication with a specific pharmacological action. It is officially classified as a dopamine antagonist and a prokinetic drug. This is a functional classification defined by health authorities and is distinct from a vitamin or dietary supplement, which is intended to provide nutritional support.


Q: What is the risk of dependence or addiction with Tilidon?

The product monograph does not classify the drug as having a risk for addiction. However, reports have examined the possibility of experiencing psychiatric withdrawal events (such as anxiety or depression) following the abrupt discontinuation of the drug.


Q: Do studies suggest Tilidon is effective for its intended use?

Official documents state the drug is indicated for the relief of nausea and prevention of vomiting. Research evidence is based on short-term Randomized Controlled Trials that examined outcomes related to changes in symptoms, such as the reduction in nausea scores and the frequency of vomiting episodes.


Q: Does Tilidon have a risk of causing stomach issues?

Since the drug is a prokinetic that acts on the digestive system, some adverse reactions involve the gastrointestinal tract. The most frequently reported effect is dry mouth. Other reported effects categorized as Uncommon often involve the gastrointestinal system, such as diarrhea.


Q: Is Tilidon available over-the-counter?

The regulatory status indicates the drug is classified as a prescription-only medicine. It is not available for purchase over-the-counter.


Q: Can Tilidon cause problems with vision?

Official safety information lists some potential effects involving the eyes, although these are not commonly reported. These have included issues such as itchy eyes or crusty eyelids with discharge.


Q: Is it possible to be allergic to Tilidon?

Official information indicates the possibility of an allergy. The official label includes a contraindication for individuals with a known hypersensitivity or allergy to the drug or any of its ingredients. Severe anaphylactic reactions, which are life-threatening allergic responses, are also officially documented as a possible rare adverse reaction.

How should Tilidon be stored and disposed of?

Storage and Disposal of Tilidon

Tilidon (Domperidone) must be stored and handled according to specific official instructions to maintain its stability and ensure safety.


Storage Requirements

Detail Requirement
Temperature Store below 30 C (86 F); typically at controlled room temperature.
Protection Keep in the original container, protected from light and moisture. Do not freeze.
Child Safety Must be kept out of the sight and reach of children.
Liquid Forms Keep the container tightly closed. Oral suspension has a 12-week shelf-life after opening.

Disposal Instructions

Expired or unused Tilidon must be discarded responsibly. Disposal must be carried out in accordance with local pharmaceutical waste regulations and must not be done via wastewater (e.g., flushing) or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tilidon found in:

A-Z Index: